宜明昂科-B（01541.HK）今日盘中大涨9.73%，引起投资者广泛关注。该股价的强劲表现与公司最新发布的临床试验进展密切相关。
根据公司公告，宜明昂科-B与Instil Bio, Inc.（TIL）共同宣布了IMM2510/AXN-2510的临床最新情况及未来计划。公司预计将于今年第三季度在中国内地完成IMM2510/AXN-2510联合化疗治疗一线非小细胞肺癌（NSCLC）患者的2期试验，约60名患者将完成入组。更重要的是，这项2期试验的初步安全性及有效性结果预计将于今年下半年公布，这无疑增强了投资者对公司研发能力的信心。
IMM2510/AXN-2510是一种创新型PD-L1和VEGF的双特异性抗体，目前正在开发用于治疗多种实体肿瘤癌症。该药物的3期试验预计将于明年年中在中国内地启动，目前正在与监管部门进行商讨。这一系列积极的临床进展表明，宜明昂科-B在肿瘤治疗领域的研发实力正在不断提升，有望在未来为公司带来可观的市场机遇。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.